Displaying 1 - 20 of 5142
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill Federal Trade Commission - In the Matter of Ferrellgas Partners, L.P., et al.
Federal Trade Commission Act
Clayton Act
FTC Order Preserves Competition in Digital Advertising Ecosystem as Part of Publicis’s Acquisition of LiveRamp
Publicis-LiveRamp, In the Matter of
The FTC has taken steps to preserve competition in the digital advertising ecosystem by requiring Publicis Groupe S.A. to continue providing neutral and nondiscriminatory access to LiveRamp Holdings Inc.’s products and services, and to establish firewalls to prevent Publicis from accessing LiveRamp’s customer data, in order to complete Publicis’s acquisition of the company.
PlayPower, Inc./BCI Acquisitions, Inc., FTC, et al. v.
FTC Sues to Block PlayPower’s Acquisition of Rival Playground Manufacturer Burke
Statement of Commissioner Mark R. Meador Regarding Federal Trade Commission et al. v. Martin Shkreli
FTC, States Ask Federal Court to Hold Martin Shkreli in Contempt for Allegedly Violating Lifetime Ban from Pharmaceutical Industry
Vyera Pharmaceuticals, LLC
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
On October 13, 2026, the FTC and seven states asked a federal judge to hold “Pharma Bro” Martin Shkreli in contempt based on their allegations that he flagrantly and repeatedly violated a 2022 court order that banned him from the pharmaceutical industry.